Scienture Holdings Stock
Scienture Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- United States
- CEO
- Shankar Hariharan
- Employees
- 9
- Market cap
- $6 M
- IPO
- 06/02/2014
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for…
Scienture Holdings stock: price history
1D
-0.6%
1W
-10.6%
1M
-59.4%
6M
-66.0%
YTD
-73.6%
1Y
-77.2%
2Y
-98.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~8% weaker price swings than usual
Ask the agents about Scienture Holdings
Scienture Holdings stock metrics
P/E
-0.07
P/B
0.08
EV/EBITDA
-0.23
RETURN ON EQUITY
-4.4%
NET MARGIN
-821.3%
DEBT/EQUITY
0.17
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.9%
FLOAT SHARES
1,279,871
AVG. DAILY VOLUME (30D)
305,397
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Scienture Holdings stock
What does Scienture Holdings do?
Scienture Holdings, Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Shankar Hariharan, the company employs around 9 people.
The IPO was on 06/02/2014; the stock trades on NASDAQ under the ticker SCNX.
When does Scienture Holdings report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -8% stronger than usual.
Does Scienture Holdings pay a dividend?
Yes. The last dividend was US$1.50 per share, ex-date 19/07/2024, paid on 24/07/2024.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Scienture Holdings?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck &.
How can I get Scienture Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Scienture Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.